● Covered by 1 source · 1 reportLow impact1 neutral
FDA Approves Rasonque, a RAS Inhibitor, for Metastatic Pancreatic Cancer
Key points
- FDA approved Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma.
- Rasonque is a daily tablet targeting RAS protein, a driver of tumor growth.
- Clinical trials showed Rasonque improved median overall survival to 13.2 months.
- The approval was granted 6.5 months ahead of the user fee deadline.
New Treatment for Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has approved Rasonque (daraxonrasib), a RAS inhibitor, for the treatment of metastatic pancreatic adenocarcinoma. This approval offers a new therapeutic option for adults who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
Mechanism of Action
Rasonque is a once-daily tablet designed to target multiple forms of the RAS protein. The RAS protein is a key driver of tumor growth in most patients with pancreatic adenocarcinoma, which originates from cells lining the ducts of the pancreas.
Clinical Trial Results
In a randomized, open-label, multicenter clinical trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma, Rasonque demonstrated an improvement in median overall survival. Patients treated with Rasonque achieved a median overall survival of 13.2 months, compared to 6.7 months for those receiving standard chemotherapy.
Expedited Approval Process
The FDA granted Rasonque Breakthrough Therapy and Orphan Drug designations, leading to an expedited review process. The approval was issued 6.5 months ahead of the user fee deadline, reflecting the agency's commitment to accelerating the availability of new treatments for serious and life-threatening conditions like pancreatic cancer.
Impact on Patients
Pancreatic adenocarcinoma accounts for approximately 90% to 95% of the 67,000 new pancreatic cancer cases diagnosed annually in the U.S. Despite representing a smaller percentage of all cancer diagnoses, it contributes disproportionately to cancer deaths due to late detection, aggressive progression, and historically limited treatment options. This new approval provides a critical option for patients facing this difficult disease.
✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →
The daily brief
One email each morning: the day's tech stories, clustered across outlets and summarized. No account needed.
One email a day. Unsubscribe in one click, any time.
Today's brief
Spend a few minutes, get the whole day. Every topic's top stories in one hands-free rundown — listen, watch, or read the transcript.
▶ Play today's brief
New every morning, and the back catalogue is archived by date.
Reporting from
The U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib), a RAS inhibitor, for treating metastatic pancreatic adenocarcinoma. This approval provides a new targeted therapy option for patients with advanced pancreatic cancer, a disease with historically limited treatment options.